2024
Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM)
Buono F, Larkin K, Zempsky W, Grau L, Martin S. Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM). American Journal Of Medical Genetics Part A 2024, 194: e63541. PMID: 38234177, DOI: 10.1002/ajmg.a.63541.Peer-Reviewed Original ResearchNeurofibromatosis type 1Chronic painImpact of CPPain modulationPain regionsModerate pain severityType 1Autosomal dominant genetic disorderCross-sectional studyQuality of lifeDominant genetic disorderMedical providersPain severitySensitive clinical measureDaily functioningClinical measuresPainEffective treatmentGenetic disordersNeurofibromatosisClinical assessmentMultiple domainsAdultsQuantitative responseProviders
2023
Work readiness and barriers to employment during COVID-19 for individuals with Neurofibromatosis Type 1 (NF1)
Buono F, Polonsky M, Marks A, Larkin K, Sprong M. Work readiness and barriers to employment during COVID-19 for individuals with Neurofibromatosis Type 1 (NF1). Work 2023, 76: 1265-1273. PMID: 37355921, DOI: 10.3233/wor-220259.Peer-Reviewed Original Research
2022
Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
Buono FD, Gleed C, Boldin M, Aviles A, Wheeler N. Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial. JMIR Research Protocols 2022, 11: e30186. PMID: 35029534, PMCID: PMC8800086, DOI: 10.2196/30186.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERAlcohol use disorderQuality of lifeBlood alcohol concentrationUse disordersAlcohol use disorder populationTreatment providersPsychological distressRandomized clinical trialsLong-term treatmentTreatment motivationCost-effective treatmentControlled TrialsDisease management approachTreatment modalitiesChronic disordersAlcohol concentrationClinical trialsDropout ratePreliminary effectivenessAlcohol dependenceTimely interventionDisorder populationMonthsHigher likelihood
2021
The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with Neurofibromatosis Type 1
Buono FD, Sprong ME, Paul E, Martin S, Larkin K, Garakani A. The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with Neurofibromatosis Type 1. Orphanet Journal Of Rare Diseases 2021, 16: 234. PMID: 34020694, PMCID: PMC8138923, DOI: 10.1186/s13023-021-01866-6.Peer-Reviewed Original Research